Hemorrhagic Disorders: Clinical Trials

3140 completed, 852 recruiting, 716 unknown, 706 terminated. 2234 Phase 2, 1639 Phase 1, 826 Phase 3, 673 Not applicable, 209 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	2234	Completed 1057, Terminated 339, Recruiting 254, Unknown 213, Active not recruiting 183, Withdrawn 109, Not yet recruiting 69, Suspended 6, Enrolling by invitation 4
Phase 1	1639	Completed 794, Terminated 274, Recruiting 213, Unknown 133, Active not recruiting 103, Withdrawn 58, Not yet recruiting 55, Suspended 7, Enrolling by invitation 2
Phase 3	826	Completed 464, Recruiting 95, Active not recruiting 78, Unknown 74, Terminated 64, Not yet recruiting 25, Withdrawn 24, Suspended 2
Not applicable	673	Completed 297, Recruiting 112, Unknown 97, Terminated 65, Not yet recruiting 54, Withdrawn 20, Active not recruiting 18, Enrolling by invitation 7, Suspended 3
Phase 4	209	Completed 107, Unknown 33, Recruiting 27, Terminated 15, Withdrawn 11, Active not recruiting 8, Not yet recruiting 8
Early Phase 1	112	Recruiting 34, Unknown 28, Completed 15, Not yet recruiting 15, Terminated 9, Active not recruiting 5, Withdrawn 4, Suspended 2

Follow Hemorrhagic Disorders: new trials by email Literature Review of Hemorrhagic Disorders trials Research Report on Hemorrhagic Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders Ginger, Placebo - Women With Coagulation Disorders	Early Phase 1	Not yet recruiting	University of Valladolid	74	2028-02-01	2026-05-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors	Not applicable	Not yet recruiting	University of Vermont Medical Center	33	2028-02-01	2026-08-25
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM)	Phase 2	Not yet recruiting	Excyte Biopharma Ltd	64	2027-12-01	2026-11-06
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma Individual Exercise, Group Exercise - Multiple Myeloma	Not applicable	Suspended	Medical University of Vienna	45	2027-09-01	2026-10-09
Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy • Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy	Phase 2	Not yet recruiting	University Hospital, Strasbourg, France	120	2027-08-01	2026-08-20
Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2027-06-30	2026-11-02
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma	Phase 1	Withdrawn	Fred Hutchinson Cancer Center		2027-06-01	2026-09-11
Lentiviral FIX Gene Therapy YUVA-GT-F901 - Hemophilia B	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2027-06-01	2026-11-02
Lentiviral FVIII Gene Therapy YUVA-GT-F801 - Hemophilia A	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2027-06-01	2026-10-30
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 2	Recruiting	National Cancer Institute (NCI)	80	2027-05-22	2026-11-04
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 1 / Phase 2	Recruiting	National Cancer Institute (NCI)	162	2027-04-12	2026-10-16
Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in India Octocog alfa - Severe Hemophilia A		Not yet recruiting	Bayer	30	2027-04-05	2026-10-21
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)	Phase 2	Not yet recruiting	Zealand University Hospital	150	2027-03-01	2026-09-25
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM)	Phase 2	Not yet recruiting	University of Arkansas	50	2027-03-01	2026-09-02
An Exercise and Lifestyle Programme for Adults With Vascular Ehlers-Danlos Syndrome: A Feasibility Study Co-designed exercise-based lifestyle intervention - Vascular Ehlers Danlos Syndrome	Not applicable	Not yet recruiting	Sheffield Hallam University	40	2027-03-01	2026-07-13
Multicomponent Pain Self-Management in Adults With Haemophilic Arthropathy Multicomponent pain self-management programme - Hemophilic Arthropathy, Chronic Pain	Not applicable	Not yet recruiting	Investigación en Hemofilia y Fisioterapia	70	2027-03-01	2026-10-06
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma	Phase 4	Not yet recruiting	Anne Louise Tølbøll Sørensen	400	2027-03-01	2026-03-16
Topical TOR-582 Treatment of Epistaxis in HHT Topical sirolimus ointment - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis	Phase 1	Not yet recruiting	Columbia University	27	2027-03-01	2026-11-06
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma	Phase 1	Not yet recruiting	University of Chicago	32	2027-02-23	2026-10-22
Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia	Phase 2	Not yet recruiting	Massachusetts General Hospital	24	2027-02-19	2026-09-01

Showing 20 of 6420. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (3675)  ·  Hemophilia A (790)  ·  Lymphoma, Non-Hodgkin (613)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (598)  ·  Lymphoma (582)  ·  Neoplasms, Plasma Cell (527)  ·  Waldenstrom Macroglobulinemia (521)  ·  Lymphoma, Follicular (493)  ·  Purpura, Thrombocytopenic, Idiopathic (483)  ·  Lymphoma, B-Cell, Marginal Zone (470)  ·  Lymphoma, Mantle-Cell (466)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (464)  ·  Hodgkin Disease (453)  ·  Recurrence (437)  ·  Lymphoma, Large B-Cell, Diffuse (426)

Broader conditions

Hemic and Lymphatic Diseases (6419)  ·  Hematologic Diseases (6289)  ·  Cardiovascular Diseases (4710)  ·  Vascular Diseases (4702)  ·  Immune System Diseases (4627)  ·  Hemostatic Disorders (4303)  ·  Neoplasms by Histologic Type (4103)  ·  Immunoproliferative Disorders (4062)  ·  Blood Protein Disorders (4036)  ·  Lymphoproliferative Disorders (4015)  ·  Paraproteinemias (4003)  ·  Neoplasms (3980)  ·  Neoplasms, Plasma Cell (3511)  ·  Pathological Conditions, Signs and Symptoms (2026)

Interventions

Dexamethasone (901)  ·  Bortezomib (489)  ·  Lenalidomide (463)  ·  Cyclophosphamide (391)  ·  Melphalan (267)  ·  Calcium Dobesilate (250)  ·  daratumumab (243)  ·  pomalidomide (219)  ·  carfilzomib (187)  ·  Rituximab (170)  ·  fludarabine phosphate (159)  ·  Peripheral Blood Stem Cell Transplantation (145)  ·  Factor VIII (136)  ·  fludarabine (133)  ·  Thalidomide (132)

Sponsors

National Cancer Institute (NCI) (192)  ·  Mayo Clinic (106)  ·  Celgene (93)  ·  Institute of Hematology & Blood Diseases Hospital, China (93)  ·  Fred Hutchinson Cancer Center (92)  ·  Memorial Sloan Kettering Cancer Center (84)  ·  Novo Nordisk A/S (84)  ·  Pfizer (82)  ·  M.D. Anderson Cancer Center (77)  ·  Janssen Research & Development, LLC (68)  ·  Bayer (65)  ·  Amgen (60)  ·  Baxalta now part of Shire (58)  ·  University of Arkansas (57)  ·  Peking University People's Hospital (56)

Countries

United States (3204)  ·  France (807)  ·  China (781)  ·  Spain (614)  ·  Italy (600)  ·  Germany (597)  ·  United Kingdom (559)  ·  Canada (483)  ·  Australia (353)  ·  Japan (305)  ·  Netherlands (282)  ·  Poland (279)  ·  South Korea (259)  ·  Belgium (252)  ·  Greece (235)

Top investigators

Lei Zhang, MD (26)

Results publications

PMID 32499241, PMID 33357481, PMID 40750723, PMID 31221778, PMID 37022569, PMID 19005182, PMID 22689675, PMID 26196195, PMID 33218965, PMID 34398557, PMID 35285981, PMID 36853224, PMID 37192741, PMID 40386832, PMID 40501401, PMID 42698050, PMID 19216617, PMID 19671919, PMID 24802773, PMID 28803351, PMID 34289038, PMID 35244208, PMID 35549810, PMID 35939785, PMID 35985959, PMID 36100310, PMID 36408876, PMID 40000533, PMID 40826257, PMID 42287565, PMID 18000608, PMID 19846889, PMID 20661232, PMID 22674807, PMID 23897961, PMID 24586400, PMID 25261096, PMID 25495795, PMID 25628469, PMID 26231455, PMID 26688484, PMID 26931631, PMID 29567784, PMID 31697801, PMID 33719084, PMID 33995988, PMID 34182226, PMID 34515338, PMID 34922648, PMID 35075289

NIH funding

2023 (102), P30CA015083 (56), 2017 (43), U10CA180820 (43), 2019 (41), 2018 (40), 2016 (38), P30CA015704 (34), 2014 (33), 2009 (30), 2015 (30), 2025 (30), 2008 (26), P30CA006973 (22), P30CA033572 (22)